Advances and reflections on conversion therapy for gallbladder cancer
10.3760/cma.j.cn115396-20240705-00213
- VernacularTitle:胆囊癌转化治疗的进展和思考
- Author:
Yuzhu XIAO
1
;
Jingdong LI
;
Mingyu HU
;
Jie HUANG
Author Information
1. 川北医学院附属医院肝胆外科 川北医学院肝胆胰肠疾病研究所，南充 637000
- Keywords:
Gallbladder neoplasms;
Immunotherapy;
Antineoplastic combined chemotherapy protocols;
Translational therapy
- From:
International Journal of Surgery
2024;51(8):571-576
- CountryChina
- Language:Chinese
-
Abstract:
With the advancement of comprehensive treatment and minimally invasive technology, patients with originally unresectable gallbladder cancer are expected to undergo surgical treatment after transformational therapy, which can achieve the effect of increasing R0 resection rate and improving long-term prognosis. Conversion therapy as a new option for patients with gallbladder cancer who are difficult to undergo radical surgery is still subject to much debate. Patients with locally progressive gallbladder cancer at the initial diagnosis may be the target population for conversion therapy. Gemcitabine+ cisplatin is still used as the standard first-line chemotherapy regimen. The use of multiple chemotherapeutic agents in combination also shows new vitality. High-throughput sequencing and the use of precision targeting drugs will become new trends in the future. The use of immune drugs is still needed. And the use of immunotherapy drugs is still in demand. High-throughput sequencing and the use of precision-targeted drugs will become a new trend in the future, the use of immunologic drugs still needs more evidence-based medical support, and the use of post-translational minimally invasive techniques may bring benefits to patients.
